• Home
  • Search Results
  • Aerosol phage therapy efficacy in Burkholderia cepacia complex respiratory infections.

Aerosol phage therapy efficacy in Burkholderia cepacia complex respiratory infections.

Antimicrobial agents and chemotherapy (2014-05-07)
Diana D Semler, Amanda D Goudie, Warren H Finlay, Jonathan J Dennis
ABSTRACT

Phage therapy has been suggested as a potential treatment for highly antibiotic-resistant bacteria, such as the species of the Burkholderia cepacia complex (BCC). To address this hypothesis, experimental B. cenocepacia respiratory infections were established in mice using a nebulizer and a nose-only inhalation device. Following infection, the mice were treated with one of five B. cenocepacia-specific phages delivered as either an aerosol or intraperitoneal injection. The bacterial and phage titers within the lungs were assayed 2 days after treatment, and mice that received the aerosolized phage therapy demonstrated significant decreases in bacterial loads. Differences in phage activity were observed in vivo. Mice that received phage treatment by intraperitoneal injection did not demonstrate significantly reduced bacterial loads, although phage particles were isolated from their lung tissue. Based on these data, aerosol phage therapy appears to be an effective method for treating highly antibiotic-resistant bacterial respiratory infections, including those caused by BCC bacteria.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Ampicillin, anhydrous, 96.0-102.0% (anhydrous basis)
Supelco
Ampicillin, analytical standard
Sigma-Aldrich
Ampicillin, meets USP testing specifications
Sigma-Aldrich
Xylazine, ≥99%
USP
Ampicillin, United States Pharmacopeia (USP) Reference Standard
Ampicillin, anhydrous, European Pharmacopoeia (EP) Reference Standard